Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 9/20 | 0.49 |
| ▸ | JAK1 | P23458 | 7/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22620168 | 1.00 | JAK3 (0.49) | JAK3JAK1PDE4BPOLB | |
| SCHEMBL22613075 | 0.91 | BCHE (0.40) | JAK3JAK1 | |
| SCHEMBL22613074 | 0.91 | BCHE (0.40) | JAK3JAK1 | |
| SCHEMBL22620156 | 0.89 | JAK3 (0.42) | JAK3JAK1PDE4B | |
| SCHEMBL29855767 | 0.88 | HDAC4 (0.40) | JAK1 | |
| SCHEMBL22620109 | 0.88 | HDAC4 (0.40) | JAK1 | |
| SCHEMBL22613117 | 0.87 | JAK3 (0.37) | JAK3JAK1PDE4B | |
| SCHEMBL22620116 | 0.87 | JAK3 (0.37) | JAK3JAK1PDE4B | |
| SCHEMBL22620167 | 0.87 | HDAC4 (0.39) | JAK3JAK1PDE4B | |
| SCHEMBL22620108 | 0.87 | JAK3 (0.42) | JAK3JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220372034-A1 | SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS | ACLARIS THERAPEUTICS, INC. | 2022-11-24 | — | — | US | disclosed |
| US-11420966-B2 | Substituted pyrrolopyridines as JAK inhibitors | ACLARIS THERAPEUTICS, INC. | 2022-08-23 | — | — | US | disclosed |
| US-20200347053-A1 | SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS | ACLARIS THERAPEUTICS, INC. | 2020-11-05 | — | — | US | disclosed |
| WO-2020223728-A1 | SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS | ACLARIS THERAPEUTICS, INC. (US) | 2020-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347053-A1 | SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | JAK3 2/4885JAK1 1/4885PDE4B 509/4885 |
| US-20220372034-A1 | SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | JAK3 2/4885JAK1 1/4885PDE4B 509/4885 |
| US-11420966-B2 | Substituted pyrrolopyridines as JAK inhibitors | JAK1, JAK3, JAK2 | JAK3 2/4885JAK1 1/4885PDE4B 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.